ESTRO 2024 - Abstract Book

S2724

Interdisciplinary - Global health

ESTRO 2024

treatments. At completion of radiotherapy, ≥2 grade toxicity was reported by 5% (n=6) of participants for GI and 7% (n=9) for GU, whereas at three months following completion of radiotherapy, ≥2 grade toxicity was reported by none and 1% (n=1) of participants for GI and GU, respectively.

Conclusion:

These data demonstrate that HFRT for localized PCa is feasible in Africa and results in acute GI and GU toxicities similar and even lower to those seen in HFRT trials from Europe (≥2 grade toxicity in 38% and 49% [4 weeks after HFRT start] and 3% and 5% [18 weeks after HFRT start] of participants for GI and GU respectively). Patients will continue to be monitored to evaluate treatment outcomes and late toxicities up for up to two years. Future plans include validating these findings at additional facilities in Africa.

Keywords: Africa, hypofractionated radiotherapy, prostate

312

Poster Discussion

Greening the fight cancer: unveiling the environmental advantages of hypofractionated radiotherapy

Elías Gomis Sellés, Blas David Delgado León, Óscar Muñoz Muñoz, Manuel Borrego Reina, José Luis López Guerra

University Hospital Virgen del Rocío, Radiation Oncology, Seville, Spain

Purpose/Objective:

Greening the fight against cancer represents a vital frontier in the ongoing battle against this disease. The adoption of hypofractionated radiotherapy, not only promises treatment outcomes but also unveils a host of environmental advantages. The purpose is to investigate the real environmental benefits of adopting hypofractionated radiotherapy as a treatment approach for cancer. This research aims to quantify and highlight the reduced carbon footprint associated with hypofractionation compared to normofractionated treatments; ultimately advocating for more sustainable healthcare practices in the fight against cancer.

Material/Methods:

Observational assessment of patients undergoing adjuvant radiation therapy for breast cancer from 2015 to 2023. There were 2,069 breast cancer patients who lived within an area of 14,036 km2. Total accumulated distance traveled for all patients was 2,076,207 km. The mean distance between patient's address and the hospital was 38.12 km (median 21 km, range 7-134 km), with a mean distance traveled by patients during the entire treatment period of 1003.5 km/patient (range 24-6700 km). In terms of radiation technique, 924 patients (44.7%) were treated with 3DCRT, 1019 (49.3%) with IMRT, and 56 (2.7%) with VMAT. According to fractionation schedule: 67 (3.2%) patients received a normofractionated treatment of 25-30 fractions (50-60Gy), 1188 (57.4%) patients received hypofractionated treatment in 15 fractions (40-48Gy)